Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.

Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR.

Oncogene. 2019 Jul;38(28):5746. doi: 10.1038/s41388-019-0835-1.

PMID:
31147600
2.

Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.

Wagner S, Vlachogiannis G, De Haven Brandon A, Valenti M, Box G, Jenkins L, Mancusi C, Self A, Manodoro F, Assiotis I, Robinson P, Chauhan R, Rust AG, Matthews N, Eason K, Khan K, Starling N, Cunningham D, Sadanandam A, Isacke CM, Kirkin V, Valeri N, Whittaker SR.

Oncogene. 2019 Mar;38(10):1717-1733. doi: 10.1038/s41388-018-0554-z. Epub 2018 Oct 23. Erratum in: Oncogene. 2019 May 30;:.

3.

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.

Whittaker SR, Barlow C, Martin MP, Mancusi C, Wagner S, Self A, Barrie E, Te Poele R, Sharp S, Brown N, Wilson S, Jackson W, Fischer PM, Clarke PA, Walton MI, McDonald E, Blagg J, Noble M, Garrett MD, Workman P.

Mol Oncol. 2018 Mar;12(3):287-304. doi: 10.1002/1878-0261.12148. Epub 2018 Jan 28.

4.

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Whittaker SR, Mallinger A, Workman P, Clarke PA.

Pharmacol Ther. 2017 May;173:83-105. doi: 10.1016/j.pharmthera.2017.02.008. Epub 2017 Feb 5. Review.

5.

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.

Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA.

Mol Cancer Ther. 2015 Dec;14(12):2700-11. doi: 10.1158/1535-7163.MCT-15-0136-T. Epub 2015 Sep 8.

6.

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA.

Cancer Discov. 2013 Mar;3(3):350-62. doi: 10.1158/2159-8290.CD-12-0470. Epub 2013 Jan 3.

7.

Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold.

Niculescu-Duvaz I, Roman E, Whittaker SR, Friedlos F, Kirk R, Scanlon IJ, Davies LC, Niculescu-Duvaz D, Marais R, Springer CJ.

J Med Chem. 2008 Jun 12;51(11):3261-74. doi: 10.1021/jm070776b. Epub 2008 May 13.

PMID:
18473434
8.

The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.

Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P.

Cell Cycle. 2007 Dec 15;6(24):3114-31. Epub 2007 Oct 5.

PMID:
18075315
9.

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.

Niculescu-Duvaz I, Roman E, Whittaker SR, Friedlos F, Kirk R, Scanlon IJ, Davies LC, Niculescu-Duvaz D, Marais R, Springer CJ.

J Med Chem. 2006 Jan 12;49(1):407-16.

PMID:
16392826
10.

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

Raynaud FI, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE, Garrett MD, Rogers P, Clarke SJ, Kelland LR, Valenti M, Brunton L, Eccles S, Lane DP, Workman P.

Clin Cancer Res. 2005 Jul 1;11(13):4875-87.

12.

SECRETION OF CATECHOLAMINES IN MALIGNANT PHAEOCHROMOCYTOMA.

ROBINSON R, SMITH P, WHITTAKER SR.

Br Med J. 1964 May 30;1(5395):1422-4. No abstract available.

14.

Hashimoto's disease, dermatomyositis, and ovarian carcinoma.

CHAMBERLAIN MJ, WHITTAKER SR.

Lancet. 1963 Jun 29;1(7296):1398-9. No abstract available.

PMID:
14019939
15.

Methyldopa and hypertension.

WHITTAKER SR, ROBINSON R, STOTT AW.

Br Med J. 1963 Mar 9;1(5331):681. No abstract available.

16.

Repair of acquired interventricular septal defect following myocardial infarction.

COLLIS JL, MACKINNON J, RAISON JC, WHITTAKER SR.

Lancet. 1962 Jul 28;2(7248):172-5. No abstract available.

PMID:
13880628
17.

Acute and latent porphyria.

WHITTAKER SR, WHITEHEAD TP.

Lancet. 1956 Apr 28;270(6922):547-51. No abstract available.

PMID:
13320802
18.

Pituitary gland in clinical practice.

WHITTAKER SR.

Med Illus. 1955 Jun;9(6):375-80. No abstract available.

PMID:
14393312
19.

A method for the determination of glutamine in cerebrospinal fluid and the results in hepatic coma.

WHITEHEAD TP, WHITTAKER SR.

J Clin Pathol. 1955 Feb;8(1):81-4. No abstract available.

20.

Dissecting aortic aneurysm in Marfan's syndrome.

WHITTAKER SR, SHEEHAN JD.

Lancet. 1954 Oct 16;267(6842):791-2. No abstract available.

PMID:
13213040
21.

The diagnosis and treatment of hypopituitarism.

WHITTAKER SR, WHITEHEAD TP.

Br Med J. 1954 Jul 31;2(4882):265-9. No abstract available.

22.

Sandfly Fever in the Middle East.

Cullinan ER, Whittaker SR.

Br Med J. 1943 Oct 30;2(4321):543-5. No abstract available.

23.

Supplemental Content

Loading ...
Support Center